

RESEARCH ARTICLE

Unmasking a silent killer: Prevalence of diagnosed and undiagnosed diabetes mellitus among people living with HIV in rural South Africa

Annemiek E. M. de Vries¹ | Zanele Xaba¹ | Sehulong R. Moraba² | Luise Goerlitz^{2,3} | Hugo A. Tempelman² | Kerstin Klipstein-Grobusch^{1,4} | Lucas E. Hermans^{2,5,6} | Karine Scheuermaier⁷ | Walter L. J. M. Devillé^{1,2} | Alinda G. Vos^{1,5}

¹Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

²Ndlovu Care Group, Groblersdal, South Africa

³Infectious Disease Epidemiology, Robert Koch Institut, Berlin, Germany

⁴Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

⁵Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands

⁶Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

⁷Wits Sleep Laboratory, Brain Function Research Group, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa

Correspondence

Alinda G. Vos, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, 3584 CX Utrecht, The Netherlands.
Email: a.g.vos-8@umcutrecht.nl

Funding information

Ndlovu Care Group and the Otto Kranendonkfonds—Dutch Association of Tropical Health

Abstract

Objectives: To document the prevalence of impaired glucose tolerance (IGT) and undiagnosed diabetes mellitus (DM) and to identify factors associated with undiagnosed DM in people living with HIV (PLWH).

Methods: Cross-sectional study performed at Ndlovu Medical Center, Limpopo, South Africa including PLWH aged ≥ 18 years. Between August and November 2017, 356 HIV-positive participants were included. Information was collected on socio-demographics, DM symptoms and risk factors for DM. IGT and DM were diagnosed using random plasma glucose and/or HbA1c. Factors associated with undiagnosed DM were assessed by comparing participants with newly diagnosed DM to participants without DM.

Results: IGT was diagnosed in 172 (48.3%) participants. Twenty-nine (8.1%) participants met the definition of DM, of whom 17 (58.6%) were newly diagnosed. Compared to participants without DM, participants with DM were on average 5 years older, were more likely to have a positive family history for DM, were less physically active and had higher systolic blood pressure, body mass index and waist circumference. Factors associated with undiagnosed DM included age ≥ 45 years (odds ratio [OR] = 3.59) and physical inactivity (OR = 3.17).

Conclusions: The prevalence of IGT and DM among PLWH is high and more than half of DM cases were undiagnosed. Regular screening for DM in PLWH is recommended, especially in an ageing population with additional cardiovascular disease risk factors.

KEYWORDS

diabetes mellitus, epidemiology, HIV, impaired glucose tolerance, sub-Saharan Africa

INTRODUCTION

The prevalence of diabetes mellitus (DM) is rising in South Africa. In 2019, the prevalence was estimated to be 12.8% in adults, making South Africa the country with the highest prevalence of DM in Sub-Saharan Africa (SSA) [1].

In 2017, DM was the leading cause of death among females (7.3%) in South Africa and the second leading cause of death for the entire population, accounting for 5.7% of all deaths [2]. Additionally, the prevalence of impaired glucose tolerance (IGT) was 9.0% in 2019 [3]. IGT is a form of prediabetes indicating increased insulin resistance and impaired insulin production. The 5-year progression rate to DM is estimated to be 26% [1, 4, 5]. Lifestyle modifications may prevent progression of IGT to DM by 58% [6, 7].

Zanele Xaba and Sehulong R. Moraba contributed equally to this work.

Sustainable Development Goal: Good Health and Wellbeing

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors Tropical Medicine & International Health Published by John Wiley & Sons Ltd.

The alarming increase in DM prevalence coincides with the increasing number of people living with HIV (PLWH). In 2019, an estimated 7.5 million PLWH were residing in South Africa, comprising 19% of the adult population [8]. Due to the rapid roll-out of antiretroviral therapy (ART) life expectancy of PLWH has increased substantially [9]. This results in an ageing HIV-positive patient population, who is thus also more exposed to complications of ageing like non-communicable diseases (NCD).

PLWH may be at an increased risk of developing IGT and DM through direct and indirect mechanisms. ART, and to a small extent the virus itself, may induce central obesity, increased insulin resistance, lipodystrophy, dyslipidaemia and endothelial dysfunction [5, 10–13], which are associated with a higher risk of developing DM and metabolic syndrome [14]. It might also be the case that a DM diagnosis is made more often in PLWH due to more regular medical visits and increased NCD screening in HIV treatment facilities [14]. In spite of this, in a population of Type 2 DM in Cameroon, HIV was associated with a higher likelihood of having a debilitating complication of DM in ageing, diabetic polyneuropathy [15].

Accordingly, DM might exert a greater impact on PLWH morbidity and mortality than on HIV-negative people. A study in Malawi found that PLWH with DM had a higher mortality rate than HIV-negative people with DM [16]. Despite the higher burden of DM, over 40% of cases in PLWH may remain undiagnosed [17]. The years of life lost due to long-term effects of DM such as cardiovascular disease could be reduced substantially by early diagnosis and adequate treatment [18].

Several initiatives have been undertaken in SSA to integrate NCD care in routine HIV care [19–21]. Integration seemed feasible and, despite challenges, several studies showed significant improvement in quality of DM care [19, 20, 22]. However, there are few reports addressing the prevalence of undiagnosed DM in HIV treatment facilities in South Africa [17]. Therefore, the primary objective of this study was to get insight in the prevalence of DM and undiagnosed DM in PLWH attending a Department of Health (DOH)-contracted HIV treatment facility in rural South Africa. As a secondary objective, this study assessed the prevalence of IGT and factors associated with undiagnosed DM.

METHODS

Study population and data collection

The DM-ALERT study is a cross-sectional study that was performed at Ndlovu Medical Center (NMC), located in Elandsdoorn, a rural area in Limpopo, South Africa. The NMC is a large rural HIV treatment facility that, at the time of the study, was contracted by the South African DOH to provide free-of-charge HIV and tuberculosis treatment. The NMC delivered ART to approximately 3700 HIV-positive patients. During the study period, ART care and monitoring was

provided in accordance with the 2015 South African National Consolidated Guidelines for HIV Management [23].

Eligible participants were aged 18 years or older, HIV-positive and on stable ART for at least 6 months. Being on stable ART was defined as receiving ART for at least 12 months, with undetectable plasma HIV-RNA load (<400 copies/mL) in the last blood analysis and no change in ART regimen in the last 6 months. Patients were eligible regardless of a known DM diagnosis. Exclusion criteria were steroid therapy and serious unstable medical conditions, such as uncontrolled infections and current AIDS-defining events.

Systematic sampling was applied to recruit patients from the waiting area at the HIV clinic (one in every four patients) over a 4-month period (August to November 2017) with the intent to recruit as many patients as possible within this time frame. Participants were interviewed by a study nurse in their preferred language (Sepedi, IsiZulu or English) using a questionnaire based on a modified version of the WHO STEPS instrument and the short International Physical Activity Questionnaire (IPAQ) [24, 25]. Information was collected on socio-demographic factors, risk factors for DM and DM symptoms experienced in the past 6 months. Physical activity was defined as being active long enough to work up a sweat, based on the categories vigorous and moderate activities of the IPAQ. For known DM patients, information about diagnosis was obtained and self-reported current treatment methods and adherence to medical treatment for DM was assessed using the questionnaire.

Adherence to ART was assessed by pill count and HAART Questionnaire Score Index, which included questions about difficulty taking medication and missed doses [26]. The maximum score of the questionnaire was 16 and a higher score indicated better adherence. Information taken from the participant's medical files included relevant medical history, medication and ART therapy history (i.e. current ART regimen and duration on ART). In routine HIV care, plasma HIV-RNA load (viral load) and CD4-positive T-lymphocyte (CD4+) counts were measured once a year. The most recent plasma viral load and CD4+ counts were retrieved by retrospective chart review.

Physical examination included measurement of weight, height, waist and hip circumference by standard procedures [27]. Afterwards, the body mass index (BMI) was calculated as kg/m². Brachial blood pressure and pulse were measured three times after a 5-min rest on the left and the right arm and repeated at the arm with the highest value using an ambulatory blood pressure device (Rossmax, Berneck, Switzerland). For blood pressure and pulse, the mean of the three measurements was used.

Random plasma glucose (RPG) was assessed with a point-of-care finger prick test using the Accu-Chek Active® (Roche Diabetes Care). For analysis of haemoglobin A1c (HbA1c) levels, whole blood was tested using Dimension® EXL™ (Siemens Healthineers). IGT and DM were diagnosed using RPG and/or HbA1c, in accordance with the cut-off values of the American Diabetes Association: for RPG values between 7.8 and 11.0 mmol/L defined IGT as




FIGURE 1 DM status and method of diagnosis of participants. DM, diabetes mellitus; IGT, impaired glucose tolerance; HbA1c, haemoglobin A1c; RPG, random plasma glucose.

well as values ≥ 11.1 mmol/L in the absence of classic DM symptoms, while values ≥ 11.1 mmol/L in the presence of classic DM symptoms defined DM. HbA1c values between 5.7% and 6.4% were regarded to reflect IGT and values $\geq 6.5\%$ diagnosed DM [28]. For analysis, participants with IGT were included in the DM-negative group. The DM-positive group consisted of participants with newly diagnosed DM and previously diagnosed DM. For participants with a known DM diagnosis, controlled DM was defined as a HbA1c level of $\leq 7.0\%$. In case of abnormal laboratory findings, the participant was referred to one of the clinicians at the NMC.

Ethical approval

The DM-ALERT study was approved by the Human Research committee of the University of Pretoria, South Africa (ethics clearance number 60/2017) and conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki and ICH GCP Guidelines [29]. Written informed consent was obtained from all participants prior to study participation.

Statistical analysis

Data were imported into SPSS version 25 (IBM Corp., Armonk, NY) for analysis [30]. A two-sided p value < 0.05 was considered statistically significant. Descriptive data were presented as mean with standard deviation (SD), median with interquartile range (IQR) or count with percentage (%), as appropriate.

Based on literature, factors associated with an increased risk of DM included age ≥ 45 years, BMI ≥ 30 kg/m², waist circumference ≥ 102 cm for men or ≥ 88 cm for women, physical inactivity, positive family history for DM and symptoms associated with DM like nightly polydipsia [28, 31–37]. Waist circumference was preferred to BMI as

abdominal obesity is the form of obesity most strongly associated with metabolic syndrome.

To calculate the p value, the Chi-squared test was used for categorical variables. When $\geq 20\%$ of the cells had an expected count less than 5, Fisher's exact test was used. The independent samples Student's t -test was used for normally distributed continuous variables. For non-normally distributed continuous variables, the Mann-Whitney U test was used. The previously mentioned factors associated with DM were assessed by comparing participants with newly diagnosed DM to participants without DM in a univariable logistic regression analysis.

RESULTS

A total of 356 HIV-positive participants were included in the study, of whom 29 (8.1%) had DM and 172 (48.3%) IGT (Figure 1). Of participants with DM, 12 (41.4%) were previously diagnosed and 17 (58.6%) were newly diagnosed. Of the participants with a new DM diagnosis, 14 were diagnosed based on HbA1c, 2 based on HbA1c and RPG and 1 based on RPG in the presence of classic DM symptoms. Diagnosis of IGT was based on HbA1c in 151 cases, based on HbA1c and RPG in 10, and based on RPG in 11. None of the IGT cases were diagnosed based on a RPG ≥ 11.1 mmol/L in the absence of classic DM symptoms.

The mean age of participants was 43.8 years (SD 9.5 years) and 69.9% were female (Table 1). DM positive participants were on average 5 years older than DM negative participants ($p = 0.008$) (Table S1). There was no difference in other socio-demographic factors or HIV-related characteristics. DM-positive participants were physically less active ($p = 0.026$), were more likely to have a positive family history for DM ($p = 0.013$) and more frequently displayed cardiovascular risk factors such as a higher systolic blood pressure ($p = 0.016$), higher BMI ($p = 0.038$) and larger waist circumference ($p = 0.012$) compared to DM negative

TABLE 1 Participant characteristics.

	No IGT (<i>n</i> = 155)	IGT (<i>n</i> = 172)	Newly diagnosed DM (<i>n</i> = 17)	Previously diagnosed DM (<i>n</i> = 12)
Demographics and socio-economic background				
Age, mean (SD), years	41.8 (8.7)	44.8 (9.8)	46.7 (9.7)	50.4 (8.6)
Female gender	111 (71.6)	117 (68.0)	14 (82.4)	7 (58.3)
Partnership status (<i>n</i> = 355)				
Married or life partner	52 (33.8)	68 (39.5)	7 (41.2)	7 (58.3)
Single, divorced or widowed	102 (66.2)	104 (60.5)	10 (58.8)	5 (41.7)
Highest level of education				
Primary or less	16 (10.3)	13 (7.6)	2 (11.8)	0 (0.0)
Secondary or matric	113 (72.9)	127 (73.8)	12 (70.6)	9 (75.0)
College or university	26 (16.8)	32 (18.6)	3 (17.6)	3 (25.0)
Employment (<i>n</i> = 353)				
Unemployed	47 (30.3)	36 (21.3)	3 (17.6)	2 (16.7)
Employed	98 (63.2)	112 (66.3)	12 (70.6)	9 (75.0)
Other (student, retired, disabled)	10 (6.5)	21 (12.4)	2 (11.8)	1 (8.3)
Source of income				
No income	6 (3.9)	5 (2.9)	1 (5.9)	1 (8.3)
Remittance	23 (14.8)	18 (10.5)	2 (11.8)	0 (0.0)
Grants or pension	32 (20.6)	34 (19.8)	2 (11.8)	2 (16.7)
Salaries	94 (60.6)	115 (66.9)	12 (70.6)	9 (75.0)
Lifestyle, diet and risk factors for DM				
Activity long enough to work up a sweat (<i>n</i> = 354)				
Never or rarely	43 (27.9)	42 (24.6)	9 (52.9)	5 (41.7)
Sometimes	91 (59.1)	97 (56.7)	5 (29.4)	5 (41.7)
Often	20 (13.0)	32 (18.7)	3 (17.6)	2 (16.7)
Diet with daily vegetables or fruits (<i>n</i> = 351)	69 (45.1)	75 (44.4)	6 (35.3)	6 (50.0)
Positive family history for DM (<i>n</i> = 290)	36 (27.7)	40 (28.2)	4 (23.5)	6 (50.0)
HIV-related characteristics				
Time on ART, months (<i>n</i> = 355)	74 [48–104]	74 [49–98]	67 [41–104]	68 [41–127]
CD4+ cell count, cells/mm ³ (<i>n</i> = 355)	514 [338–735]	529 [332–676]	590 [432–855]	648 [362–866]
Viral load, cp/mL (<i>n</i> = 269)	50 [20–281]	73 [20–295]	50 [20–73]	238 [20–1080]
Pill count (<i>n</i> = 221)	100 [98–100]	100 [98–100]	100 [94–100]	100 [95–100]
HAART adherence score (<i>n</i> = 346)	16 [15–16]	16 [15–16]	16 [14–16]	16 [15–16]
Physical examination				
Systolic blood pressure, mmHg	119 [110–126]	121 [113–131]	125 [118–139]	128 [119–134]
Diastolic blood pressure, mmHg	81 [74–89]	83 [74–93]	81 [76–100]	89 [82–98]
Heart rate, beats per minute	73 [67–78]	73 [67–82]	75 [70–85]	80 [69–96]
Body mass index, kg/m ²	25.1 [21.8–28.9]	24.8 [21.2–30.1]	27.7 [22.8–36.0]	28.1 [24.2–31.5]
Waist circumference, cm	80 [74–87]	83 [76–91]	89 [76–101]	93 [80–100]
Hip circumference, cm	101 [94–109]	100 [92–110]	103 [96–120]	100 [96–112]
Waist:hip ratio	0.79 [0.75–0.85]	0.82 [0.77–0.88]	0.81 [0.74–0.86]	0.88 [0.81–0.98]
Laboratory analysis				
Random plasma glucose, mmol/L	5.5 [5.0–6.3]	5.8 [5.3–6.8]	8.3 [6.0–10.6]	12.5 [8.0–15.8]
HbA1c, % (<i>n</i> = 354)	5.4 [5.2–5.5]	5.9 [5.7–6.1]	6.7 [6.5–7.3]	8.5 [6.6–10.5]

Note: Data are expressed as median [IQR] or count (%) unless otherwise specified.

Abbreviations: ART, antiretroviral treatment; CD4+, CD4-positive T-lymphocyte; DM, diabetes mellitus; HbA1c, haemoglobin A1c; IGT, impaired glucose tolerance; viral load, HIV-RNA load.

participants. When comparing participants with IGT to participants without IGT, no significant differences in demographics or risk factors were observed.

Comparing DM-related symptoms, only polydipsia at night was more frequently seen in participants with DM ($p = 0.04$) (Table 2).

Of the 12 participants previously diagnosed with DM, four (33.3%) had reached the treatment goal ($\text{HbA}_{1c} \leq 7.0\%$) (Table S2). All were treated with prescription tablets, although many had medication difficulties and missed doses. In addition to this, only 1 out of 12 participants reported to currently use a diet in addition to prescription tablets. None of the participants were on insulin therapy. The date of diagnosis was available for five participants and the mean time since diagnosis was 4.8 years.

Comparing participants with newly diagnosed DM to DM-negative participants, age ≥ 45 years (odds ratio [OR] = 3.591 [95% confidence interval [CI] 1.236–10.432], $p = 0.019$) and physical inactivity (OR = 3.176 [95% CI 1.187–8.497], $p = 0.021$) were associated with a DM diagnosis (Table 3).

TABLE 2 Symptoms of DM experienced in the past 6 months.

	DM positive ($n = 29$)	DM negative ($n = 327$)	p value
Polydipsia and polyuria	13 (44.8)	94 (28.7)	0.070
Nightly polydipsia ($n = 355$)	11 (37.9)	69 (21.2)	0.038
Increased hunger	10 (34.5)	75 (22.9)	0.162
Changed weight	4 (13.8)	50 (15.3)	1.000
Fatigue	12 (41.4)	90 (27.5)	0.114
Blurred vision ($n = 355$)	10 (34.5)	107 (32.8)	0.855
Slow-healing sores or frequent infections	4 (13.8)	20 (6.1)	0.120
Tingling or numbness in hands or feet	11 (37.9)	101 (30.9)	0.434
Any symptom of DM	25 (86.2)	272 (83.2)	0.800

Note: Data are expressed as count (percentage).

Abbreviation: DM, diabetes mellitus.

DISCUSSION

This study found an overall DM prevalence of 8.1% in a population of PLWH on ART attending clinical care in a rural South African setting. Undiagnosed DM was found in 4.8% of the participating PLWH. Moreover, IGT occurred in nearly half of the participating PLWH. Factors associated with undiagnosed DM were age from 45 years and physical inactivity.

The high burden of DM is alarming as DM predisposes to morbidity and premature mortality, including cardiovascular disease and death [18]. Of the PLWH with DM, 58.6% was undiagnosed, which is roughly in line with previous studies. A systematic review on DM in SSA covering publications from 1999 to 2011 concluded that over 40% of DM was undiagnosed [11]. A study performed in South Africa reported that 43% of PLWH with DM were previously undiagnosed, although they attended clinic visits regularly [17]. This high frequency of undiagnosed DM suggests that existing screening practices in general primary care clinics might be suboptimal. The South African Adult Primary Care guideline recommends screening for DM among PLWH when patients are first diagnosed with HIV, using urine dipstick on glucose as well as an assessment of CVD risk including a Random Plasma Glucose [38]. No further routine DM screening is incorporated in the South African HIV guideline [39].

Overall, the DM prevalence of 8.1% in our study corresponds with previous studies addressing DM in PLWH. A recent systematic review and meta-analysis reported a prevalence of DM among PLWH ranging from 1.3% to 18% in low-income and middle-income countries [40]. However, studies conducted in South Africa in PLWH reported a slightly lower prevalence of 1%–5% [12, 17, 41]. The difference between our study and these studies can be explained by differences in patient populations as studies were performed in different parts of South Africa, e.g. rural and urban areas [12]. Furthermore, one study excluded participants aged above 45 years [41]. Additionally, different methods for diagnosing DM were used (e.g. fasting plasma

TABLE 3 Possible predicting factors for newly diagnosed DM.

	DM negative ($n = 327$)	Newly diagnosed DM ($n = 17$)	OR (95% CI)	p value
Age ≥ 45 years	131 (40.1)	12 (70.6)	3.591 (1.236–10.432)	0.019
Female gender	228 (69.7)	14 (82.4)	2.026 (0.570–7.209)	0.275
Waist circumference: male ≥ 102 or female ≥ 88 cm	75 (22.9)	7 (41.2)	2.352 (0.866–6.391)	0.094
Symptoms of DM experienced in the past 6 months				
Nightly polydipsia ($n = 343$)	69 (21.2)	6 (35.3)	2.032 (0.726–5.688)	0.177
Changed weight	50 (15.3)	2 (11.8)	0.739 (0.164–3.330)	0.693
Blurred vision ($n = 343$)	107 (32.8)	4 (23.5)	0.630 (0.201–1.978)	0.428
Slow-healing sores or frequent infections	20 (6.1)	1 (5.9)	0.959 (0.121–7.605)	0.969
Physical inactivity ($n = 342$)	85 (26.2)	9 (52.9)	3.176 (1.187–8.497)	0.021

Note: Data are expressed as count (percentage).

Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; OR, odds ratio.

glucose, HbA1c only and RPG and HbA1c) as well as more lenient cut-off points. This may all explain the lower DM frequency found in these studies.

Another finding of our study is a high frequency of IGT among PLWH of nearly 50%. This lies roughly in the same range as previous studies on IGT among PLWH where frequencies between 19% and 47% were reported [5, 7, 10]. This finding is alarming as IGT has been associated with progression to DM [5]. Early identification followed by lifestyle counselling addressing food choices, a healthy BMI and physical activity is important as lifestyle modifications decrease the likelihood of progression to DM [6, 7].

Factors associated with undiagnosed DM (age and physical inactivity) and variables with a *p* value <0.20 but not reaching statistical significance (waist circumference and nightly polydipsia), correspond with previously identified clinical risk factors for DM [28, 31, 32, 42–44].

A strength of this study is that we addressed the rate of undiagnosed DM among HIV-infected individuals in an HIV clinic in South Africa, where this was previously largely unknown. This reflects real life clinical care and adds to the knowledge gap of undiagnosed DM. Other strengths are the structured data collection and assessment of DM by means of RPG and HbA1c.

A limitation of our study is that it has a relatively small sample size which limited power and ability to examine associations in a multivariable way between risk factors and undiagnosed DM. Besides, although the study was conducted at a governmental HIV facility and hence reflects clinical care, the single-site nature of the study might limit the generalizability to other governmental clinics located in the same area or elsewhere in the county, as well as to private clinics. Furthermore, we did not have fasting blood glucose measurements and diagnosis was based on a single measurement. This can have resulted in an underestimation of the prevalence of DM, although most cases in our study were diagnosed based on HbA1c, which is a stable outcome as it reflects blood glucose levels over the course of the past 3 months [28]. However, studies suggest that using HbA1c to diagnose DM in South Africa can both underestimate and overestimate the prevalence of DM [45, 46]. In people with sickle cell trait, which may extend to more than 15% of the SSA population, HbA1c may underestimate past glycaemia due to the shorter life span of the red blood cells [47, 48]. However, another study reported that using HbA1c to define diabetes resulted in a four times increased prevalence of DM compared to the prevalence based on fasting blood glucose [46]. Finally, we did not distinguish between Type 1 DM and Type 2 DM, although no patient was on insulin therapy, suggesting that all cases were Type 2 DM.

The high rate of undiagnosed DM and IGT underlines the importance of screening for DM as part of routine HIV care. We would recommend to screen for DM at HIV diagnosis using Random Plasma Glucose or HbA1c in all patients, depending on available resources and infrastructure. The optimum screening interval has yet to be determined, but in line with the South African Adult Primary Care guideline triennial screening for patients over 45 years

and yearly screening for patients with IGT would be recommended [38]. The co-existence of HIV and DM underlines the need for integrated health care, addressing both HIV and NCDs. To achieve this, a fundamental restructuring of available resources, and increase in capacity, both in human resources and available funding is needed. If regular testing for the development of IGT or DM in patients at risk (age >45 years and physical inactive) cannot be achieved, physicians should be alert to the development of DM-related complaints.

ACKNOWLEDGEMENTS

We would like to thank all the participants for their willingness to participate, and the medical staff at Ndlovu Medical Center for their help during recruitment and inclusion.

FUNDING INFORMATION

The DM-ALERT study was funded by the Ndlovu Care Group and the Otto Kranendonkfonds—Dutch Association of Tropical Health. The funding sources were not involved at any stage of the study.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels: IDF; 2019.
2. Statistics South Africa. Mortality and causes of death in South Africa, 2017: findings from death notification. Statistical release P0309.3. Pretoria: Statistics South Africa; 2020.
3. IDF Diabetes Atlas 9th edition 2019. Age-adjusted comparative prevalence of IGT [Internet]. Available from: <https://diabetesatlas.org/data/en/indicators/6/>
4. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care*. 2007;30(3):753–9.
5. Phuphuakrat A, Nimitphong H, Reutrakul S, Sungkanuparph S. Prediabetes among HIV-infected individuals receiving antiretroviral therapy: prevalence, diagnostic tests, and associated factors. *AIDS Res Ther*. 2020;17(1):25.
6. Pratley RE, Weyer C. Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion. *Curr Diab Rep*. 2002;2(3):242–8.
7. Njuguna B, Kiplagat J, Bloomfield GS, Pastakia SD, Vedanthan R, Koethe JR. Prevalence, risk factors, and pathophysiology of dysglycemia among people living with HIV in Sub-Saharan Africa. *J Diabetes Res*. 2018;2018:1–12.
8. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS data. 2020.
9. Trickey A, May MT, Vehreschild JJ, Obel N, Gill MJ, Crane HM, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. *Lancet HIV*. 2017;4(8):e349–56.
10. Rhee JY, Bahtila TD, Palmer D, Tih PM, Aberg JA, LeRoith D, et al. Prediabetes and diabetes among HIV-infected adults in Cameroon. *Diabetes Metab Res Rev*. 2016;32(6):544–9.
11. Hall V, Thomsen R, Henriksen O, Lohse N. Diabetes in Sub Saharan Africa 1999–2011: epidemiology and public health implications. A systematic review. *MC Public Health*. 2011;11(1):564.
12. Mashinya F, Alberts M, Van Geertruyden JP, Colebunders R. Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa: a cross sectional study. *AIDS Res Ther*. 2015;12(1):42.
13. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients. *Diabetes Care*. 2008;31(6):1224–9.

14. Oni T, Youngblood E, Boule A, McGrath N, Wilkinson RJ, Levitt NS. Patterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa: a cross sectional study. *BMC Infect Dis*. 2015;15(1):20.
15. Simo N, Kuate-Tegueu C, Ngankou-Tchankeu S, Doumbe J, Maiga Y, Cesari M, et al. Correlates of diabetic polyneuropathy of the elderly in Sub-Saharan Africa. *PLoS One*. 2020;1:15.
16. Burgess PI, Harding SP, Kayange PC, van Oosterhout J, García-Fiñana M, Msukwa G, et al. High mortality in subjects with both diabetes and HIV in sub-Saharan Africa. *AIDS*. 2018;32:2083–4.
17. Rabkin M, Mutiti A, Chung C, Zhang Y, Wei Y, El-Sadr WM. Missed opportunities to address cardiovascular disease risk factors amongst adults attending an urban HIV clinic in South Africa. *PLoS One*. 2015;10(10):e0140298.
18. Basu S, Wagner RG, Sewpaul R, Reddy P, Davies J. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. *Lancet Glob Heal*. 2019;7(2):e270–80.
19. Njuguna B, Vorkoper S, Patel P, Reid MJA, Vedanthan R, Pfaff C, et al. Models of integration of HIV and noncommunicable disease care in sub-Saharan Africa: lessons learned and evidence gaps. *Aids*. 2018;32(Suppl 1):S33–42.
20. Haldane V, Legido-Quigley H, Chuah FLH, Sigfrid L, Murphy G, Ong SE, et al. Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. *AIDS Care*. 2018;30(1):103–15.
21. Matanje Mwagomba BL, Ameh S, Bongomin P, Juma PA, Mackenzie RK, Kyobutungi C, et al. Opportunities and challenges for evidence-informed HIV-noncommunicable disease integrated care policies and programs: lessons from Malawi, South Africa, Swaziland and Kenya. *AIDS*. 2018;32:S21–32.
22. Rabkin M, Melaku Z, Bruce K, Reja A, Koler A, Tadesse Y, et al. Strengthening health systems for chronic care: leveraging HIV programs to support diabetes services in Ethiopia and Swaziland. *J Trop Med*. 2012;2012:1–6.
23. National Department of Health South Africa. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria: National Department of Health South Africa; 2015.
24. World Health Organization. Noncommunicable Diseases and Mental Health Cluster. WHO STEPS surveillance manual : the WHO STEP-wise approach to chronic disease risk factor surveillance / Noncommunicable Diseases and Mental Health, Geneva: WHO; 2005.
25. International Physical Activity Questionnaire-Short Form [Internet]. Available from: www.ipaq.ki.se
26. Mannheimer SB, Mukherjee R, Hirschhorn LR, Dougherty J, Celano SA, Ciccarone D, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. *AIDS Care*. 2006;18(7):853–61.
27. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES): Anthropometry procedures manual. 2011.
28. American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2020. *Diabetes Care*. 2020;43(Suppl. 1):S14–31.
29. International ethical guidelines for health-related research involving humans. 4th ed. Geneva: Council for International Organizations of Medical Sciences (CIOMS); 2016.
30. IBM Corp. Released 2017. IBM SPSS statistics for Macintosh, version 25.0. Armonk, NY: IBM Corp; 2017.
31. Okwechime IO, Roberson S, Odoi A. Prevalence and predictors of pre-diabetes and diabetes among adults 18 years or older in Florida: a multinomial logistic modeling approach. *PLoS One*. 2015;10(12):e0145781.
32. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. *Can J Cardiol*. 2018;34:575–84.
33. Spollett GR. Hyperglycemia in HIV/AIDS. *Diabetes Spectr*. 2006;19:163–6.
34. Pippitt K, Li M, Gurgle HE. Diabetes mellitus: screening and diagnosis. *Am Fam Physician*. 2016;93:103–9.
35. Purnell JQ. Definitions, classification, and epidemiology of obesity. [Updated 2018 Apr 12]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. *Endotext* [Internet]. South Dartmouth, MA: MDText.com, Inc.; 2000.
36. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. *Circulation*. 2005;112(17):2735–52.
37. Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. *Trends Cardiovasc Med*. 2020;30:160–4.
38. The South African National Department of Health. Adult primary care (APC) Guide 2019/2020. 2019.
39. National Department of Health South Africa. 2019 ART clinical guidelines for the management of HIV in adults, pregnancy, adolescents, children, infants and neonates. Pretoria: Department of Health; 2019.
40. Patel P, Rose CE, Collins PY, Nuche-Berenguer B, Sahasrabudhe VV, Peprah E, et al. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. *AIDS*. 2018;32:S5–20.
41. Julius H, Basu D, Ricci E, Wing J, Kusari Basu J, Pocaterra D, et al. The burden of metabolic diseases amongst HIV positive patients on HAART attending the Johannesburg hospital. *Curr HIV Res*. 2012;9(4):247–52.
42. Gray LJ, Davies MJ, Hiles S, Taub NA, Webb DR, Srinivasan BT, et al. Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. *Diabetologia*. 2012;55(4):959–66.
43. Bang H, Edwards AM, Bombardier AS, Ballantyne CM, Brillion D, Callahan MA, et al. Development and validation of a patient self-assessment score for diabetes risk. *Ann Intern Med*. 2009;151(11):775–83.
44. Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes risk calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. *Diabetes Care*. 2008;31(5):1040–5.
45. Zemlin AE, Matsha TE, Hassan MS, Erasmus RT. HbA1c of 6.5% to diagnose diabetes mellitus—does it work for us?—the Bellville South Africa study. *PLoS One*. 2011;6(8):e22558. Available from: <http://pmc/articles/PMC3155525/>.
46. Wade AN, Crowther NJ, Abrahams-Gessel S, Berkman L, George JA, Xavier Gómez-Olivé F, et al. Concordance between fasting plasma glucose and HbA1c in the diagnosis of diabetes in black South African adults: a cross-sectional study. *BMJ Open*. 2021;11:46060. Available from: <http://bmjopen.bmj.com/>
47. Lacy ME, Wellenius GA, Sumner AE, Correa A, Carnethon MR, Liem RI, et al. Association of sickle cell trait with hemoglobin A1c in African Americans. *JAMA J Am Med Assoc*. 2017;317(5):507–15. Available from: <http://pmc/articles/PMC5713881/>.
48. Williams TN. Sickle cell disease in sub-Saharan Africa. *Hematol Oncol Clin North Am*. 2016;30(2):343–58.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: de Vries AEM, Xaba Z, Moraba SR, Goerlitz L, Tempelman HA, Klipstein-Grobusch K, et al. Unmasking a silent killer: Prevalence of diagnosed and undiagnosed diabetes mellitus among people living with HIV in rural South Africa. *Trop Med Int Health*. 2023;28(5):367–73. <https://doi.org/10.1111/tmi.13871>